{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:30:48Z","timestamp":1766082648677,"version":"3.48.0"},"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ratchadapiseksompotch Endowment Fund of the Center of Excellence in Hepatic Fibrosis and Cirrhosis Research Unit","award":["GCE 3300170037"],"award-info":[{"award-number":["GCE 3300170037"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Atezolizumab plus bevacizumab (ATEZO\/BEV) and Lenvatinib (LEN) have demonstrated efficacy as first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). This study aimed to compare the efficacy, safety, and outcomes of these two treatments. Data were retrospectively collected from 163 patients with unresectable HCC receiving first-line Lenvatinib (LEN) (n\u2009=\u200985) or ATEZO\/BEV (n\u2009=\u200978) between 2020 and 2023 at Chulalongkorn University Hospital in Bangkok, Thailand. The primary outcome was overall survival (OS) following treatment. Propensity score matching (PSM) was used for analysis. The median patient age was 60.6 (SD 11.8) years; 82.2% were male. Most had hepatitis B\/C (66.9%), BCLC stage C (73%), and Child-Pugh class A cirrhosis (63.8%). After PSM analysis, overall survival (OS) was significantly longer in the ATEZO\/BEV group (12.7 vs. 7.5 months; p\u2009=\u20090.016, HR\u2009=\u20090.618, 95% CI: 0.417\u20130.916). However, there was no significant difference in progression-free survival (PFS) between ATEZO\/BEV and LEN groups (10.8 vs. 7.8 months; p\u2009=\u20090.26, HR\u2009=\u20090.73, 95% CI: 0.431\u20131.255). Assessed by mRECIST, neither objective response rate (ORR: 23.7% vs. 19.7%, p\u2009=\u20090.555) nor disease control rate (DCR: 36.8% vs. 38.2%, p\u2009=\u20090.867) differed significantly. Multivariate analysis revealed alpha-fetoprotein \u2265500\u2009ng\/mL (HR\u2009=\u20091.881, 95% CI: 1.028\u20133.443, p\u2009=\u20090.04), tumor size (HR\u2009=\u20091.833, 95% CI: 1.010\u20133.327, p\u2009=\u20090.046) and ATEZO\/BEV therapy (HR\u2009=\u20090.604, 95%CI: 0.373\u20130.977, p\u2009=\u20090.04) were independently associated with OS. Adverse event rates were comparable (ATEZO\/BEV 43.7% vs. LEN 56.3%; p\u2009=\u20090.08). In conclusion, the study demonstrates that ATEZO\/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.<\/jats:p>","DOI":"10.1371\/journal.pone.0337351","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:27:42Z","timestamp":1766082462000},"page":"e0337351","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2117-7467","authenticated-orcid":true,"given":"Sangdao","family":"Boonkaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0843-1311","authenticated-orcid":true,"given":"Chidkamon","family":"Pattarawongpaiboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panarat","family":"Thaimai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prooksa","family":"Ananchuensook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supachaya","family":"Sriphoosanaphan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suebpong","family":"Tanasanvimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattaya","family":"Teeyapun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nussara","family":"Pakvisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nipaporn","family":"Siripon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyawat","family":"Komolmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-1702","authenticated-orcid":true,"given":"Kessarin","family":"Thanapirom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"pone.0337351.ref001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"pone.0337351.ref002","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430028","article-title":"Updates on Systemic Therapy for Hepatocellular Carcinoma","volume":"44","author":"P Ntellas","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10126","key":"pone.0337351.ref003","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"pone.0337351.ref004","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11864-023-01098-9","article-title":"Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects","volume":"24","author":"B Alawyia","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"pone.0337351.ref005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"JM Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"pone.0337351.ref006","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000528272","article-title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","volume":"12","author":"M Kudo","year":"2022","journal-title":"Liver Cancer"},{"issue":"6","key":"pone.0337351.ref007","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"AG Singal","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"pone.0337351.ref008","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"6","key":"pone.0337351.ref009","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-022-00921-x","article-title":"Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis","volume":"17","author":"T Niizeki","year":"2022","journal-title":"Target Oncol"},{"issue":"20","key":"pone.0337351.ref010","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0337351.ref011","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/JHC.S284430","article-title":"An Analysis of Individual and Contextual-Level Disparities in Screening, Treatment, and Outcomes for Hepatocellular Carcinoma","volume":"8","author":"JP Kronenfeld","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"pone.0337351.ref012","doi-asserted-by":"crossref","first-page":"801981","DOI":"10.3389\/fpubh.2022.801981","article-title":"Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review","volume":"10","author":"H Zou","year":"2022","journal-title":"Front Public Health"},{"issue":"5","key":"pone.0337351.ref013","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.3390\/ijms24054286","article-title":"Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review","volume":"24","author":"E Shahini","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:27:46Z","timestamp":1766082466000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337351"}},"subtitle":[],"editor":[{"given":"Carmelo","family":"Caldarella","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0337351","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}